UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.79−0.08 (-0.27%)
Close on Nov 18, 2026Market cap $1.46BP/E –Yield –
UroGen Pharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
UroGen Pharma's profit margin for the twelve months ending Jun 30, 2026 was -51.7%. For fiscal 2025 it was -139.8%, against -140.4% the year before. The highest annual figure on record is -11.1% in fiscal 2016.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -139.8% | +0.5 |
| FY2024 | Dec 31, 2024 | -140.4% | −16.7 |
| FY2023 | Dec 31, 2023 | -123.6% | +47.0 |
| FY2022 | Dec 31, 2022 | -170.6% | +60.1 |
| FY2021 | Dec 31, 2021 | -230.7% | +858.3 |
| FY2020 | Dec 31, 2020 | -1088.9% | +583055.5 |
| FY2019 | Dec 31, 2019 | -584144.4% | −577437.3 |
| FY2018 | Dec 31, 2018 | -6707.2% | −6462.0 |
| FY2017 | Dec 31, 2017 | -245.2% | −234.1 |
| FY2016 | Dec 31, 2016 | -11.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -19.8% | +186.4 |
| Q1 FY2026 | Mar 31, 2026 | -46.3% | +170.2 |
| Q4 FY2025 | Dec 31, 2025 | -69.7% | +83.0 |
| Q3 FY2025 | Sep 30, 2025 | -121.3% | −27.4 |
| Q2 FY2025 | Jun 30, 2025 | -206.2% | −53.3 |
| Q1 FY2025 | Mar 31, 2025 | -216.5% | −44.6 |
| Q4 FY2024 | Dec 31, 2024 | -152.7% | −42.1 |
| Q3 FY2024 | Sep 30, 2024 | -93.9% | +11.0 |
| Q2 FY2024 | Jun 30, 2024 | -152.9% | −38.7 |
| Q1 FY2024 | Mar 31, 2024 | -171.9% | +3.8 |
| Q4 FY2023 | Dec 31, 2023 | -110.6% | +49.0 |
| Q3 FY2023 | Sep 30, 2023 | -104.9% | +55.5 |
| Q2 FY2023 | Jun 30, 2023 | -114.2% | +46.6 |
| Q1 FY2023 | Mar 31, 2023 | -175.7% | +33.6 |
| Q4 FY2022 | Dec 31, 2022 | -159.6% | +16.3 |
| Q3 FY2022 | Sep 30, 2022 | -160.5% | +105.7 |
| Q2 FY2022 | Jun 30, 2022 | -160.8% | +40.5 |
| Q1 FY2022 | Mar 31, 2022 | -209.3% | +137.2 |
| Q4 FY2021 | Dec 31, 2021 | -175.9% | +207.3 |
| Q3 FY2021 | Sep 30, 2021 | -266.2% | +566.4 |
| Q2 FY2021 | Jun 30, 2021 | -201.2% | +8225.9 |
| Q1 FY2021 | Mar 31, 2021 | -346.5% | +124525.7 |
| Q4 FY2020 | Dec 31, 2020 | -383.2% | +6872.3 |
| Q3 FY2020 | Sep 30, 2020 | -832.6% | +4119.6 |
| Q2 FY2020 | Jun 30, 2020 | -8427.2% | −5645.0 |
| Q2 FY2019 | Jun 30, 2019 | -124872.2% | −121787.8 |
| Q3 FY2018 | Sep 30, 2018 | -7255.5% | −7251.7 |
| Q2 FY2018 | Jun 30, 2018 | -4952.2% | +13032.0 |
| Q1 FY2018 | Mar 31, 2018 | -2782.1% | – |
| Q4 FY2017 | Dec 31, 2017 | -3084.4% | – |
| Q3 FY2017 | Sep 30, 2017 | -3.8% | – |
| Q1 FY2017 | Mar 31, 2017 | -17984.2% | – |
See a number that looks wrong?